Optimizing the use of β-blockers in the effective treatment and management of heart failure: A case study approach

American Journal of Medicine

Volumn 110, Issue 5 SUPPL. 1, 2001, Pages 11-20

  Eichhorn, Eric J ^a,c   Young, James B ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CATECHOLAMINE; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; FUROSEMIDE; INDOMETACIN; ISOSORBIDE; METOPROLOL; MILRINONE; NORADRENALIN; RENIN; WARFARIN;

ADRENERGIC SYSTEM; ANEURYSM; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG MECHANISM; FLUID RETENTION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INDIVIDUALIZATION; KIDNEY BLOOD FLOW; LABORATORY TEST; PATIENT COMPLIANCE; PATIENT EDUCATION; POLYPHARMACY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 0035794988     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(01)00667-2     Document Type: Review

References (43)

1. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
2. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure
3. Critical review of heart failure: The role of left ventricular remodeling in the therapeutic response
4. Cardiac remodeling as a consequence and cause of progressive heart failure
5. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy
6. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure
7. Plasma norepinephrine in congestive heart failure
8. The effects of norepinephrine on myocardial biology: Implications for the therapy of heart failure
9. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice
10. Adrenergic effects on the biology of the adult mammalian cardiocyte
11. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
12. The effect of digoxin on mortality and morbidity in patients with heart failure
13. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
14. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial (SAVE)
15. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
16. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
17. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
18. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial
19. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
20. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-Heart Failure)
21. Beta-adrenergic receptor blockade in chronic heart failure
22. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure
23. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II
24. Beta-blockers in heart failure: Potential of carvedilol
25. Left ventricular hypertrophy regression during antihypertensive treatment
26. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
27. Controlled trials with beta blockers in heart failure: Metoprolol as the prototype
28. Carvedilol in heart failure
29. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
30. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
31. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART
32. Safety and efficacy of carvedilol in severe heart failure
33. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment
34. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under recognized public health problem
35. Beta-blocker withdrawal: The song of Orpheus
36. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])
37. The interaction of ACE inhibitors and aspirin in heart failure: Torn between two lovers
38. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease
39. Interaction of ACE inhibitors and aspirin in patients with congestive heart failure
40. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
41. Warfarin anticoagulation and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction